C12N 2760/18671
Demonstrated in vivo effect
C12N2760/18671 (Demonstrated in vivo effect) appears on 11 US grants and 15 published applications in this corpus.
Search patents in C12N- Granted patents
- 11
- Published applications
- 15
- Assignees
- 13
- Inventors
- 30
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 1 | 2 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 1 |
| 2020 | 1 | 1 |
| 2021 | 1 | 1 |
| 2022 | 1 | 1 |
| 2023 | 1 | 2 |
| 2024 | 2 | 2 |
| 2025 | 0 | 1 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/PIV3 F protein and uses thereof2 Jun 2026US 12,643,925 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Temperature-based transient delivery of nucleic acids and proteins to cells and tissues13 Aug 2024US 12,060,568 B2Elixirgen Therapeutics, Inc.
- Recombinant human parainfluenza virus type 1 expressing a chimeric RSV/HPIV1 f protein and uses thereof25 Jun 2024US 12,018,051 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Recombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof28 Feb 2023US 11,591,372 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Temperature-based transient delivery of nucleic acids and proteins to cells and tissues23 Aug 2022US 11,421,248 B2Elixirgen Therapeutics, Inc.
- Temperature-based transient delivery of nucleic acids and proteins to cells and tissues23 Jan 2025US 2025/0027111 A1Elixirgen Therapeutics, Inc.
- Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/piv3 f protein and uses thereof19 Sep 2024US 2024/0309053 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Recombinant chimeric bovine/human parainfluenza virus 3 expressing sars-cov-2 spike protein and its use20 Jun 2024US 2024/0197861 A1The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Recombinant human/bovine parainfluenza virus 1 (hpiv1) expressing a chimeric rsv/hpiv1 f protein and uses thereof14 Sep 2023US 2023/0287055 A1The United States of America, as represented by the Secretary, Department of Health and Human Ser.
- T-cell epitopes of human parainfluenza virus 3 for adoptive t-cell immunotherapy2 Feb 2023US 2023/0036213 A1Children's National Medical Center
Most cited
By later US patents
- Attenuated parainfluenza virus (PIV) vaccines11US 7,951,383 B2The United States of America as represented by the Department of Health and Human Services · 2011
- Polypeptide promoting vascular endothelial cell growth8US 7,807,176 B2Genomidea Inc. · 2010
- Compositions and methods for the treatment of viral infections5US 9,290,545 B2Dana-Farber Cancer Institute, Inc. · 2016
- Compositions and methods comprising hydrocarbon-stapled polypeptides4US 10,259,848 B2Dana-Farber Cancer Institute, Inc. · 2019
- Recombinant human/bovine parainfluenza virus 1 (HPIV1) expressing a chimeric RSV/HPIV1 F protein and uses thereof2US 11,591,372 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2023